Othermetadata only
open_access_lmu
open_access_lmu · Other · License: Unknown
623Documents
0Full text
2026-09-05Last indexed
Recent documents from this source
- Covariation in levels of nucleotide diversity in homologous regions of the avian genome long after completion of lineage sorting#425425
- Journalism Under Duress#418960
- Deconstructing depression by machine learning: the POKAL-PSY study#418959
- Social capital in academia: How does postdocs’ relationship with their superior professors shape their career intentions?#418958
- Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020#416021
- When Stigma Meets the Sheets: Sexual Satisfaction, LGB Identity, and Shame Proneness in LGB Individuals—A Quantitative Study#416020
- Der Cluster Headache Impact Questionnaire#416019
- Static recrystallization of shocked calcite in Ries impact breccias#412770
- Resident and recruited macrophages differentially contribute to cardiac healing after myocardial ischemia#412769
- Homeostasis of megakaryocytes: balancing tissue residency and consumptive platelet production#412768
- Revisiting opinion leadership in the digital realm: Social media influencers as proximal mass opinion leaders#412767
- From Silence to Resistance: Second-Generation Palestinians in Germany#412766
- A fully iPS-cell-derived 3D model of the human blood–brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions#412765
- Theorizing communication. The production of theory in communication journals#412764
- Refining visceral adipose tissue quantification: Influence of sex, age, and BMI on single slice estimation in 3D MRI of the German National Cohort#412763
- BACE1 regulates sleep–wake cycle through both enzymatic and non–enzymatic actions#412762
- Recessive variants in mitochondrial Complex I nuclear subunits are an underrated cause of optic atrophy#412761
- Clinical utility of digital technologies in Parkinson’s disease#412760
- Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial#412759
- De novo protein-coding gene variants in developmental stuttering#412758
Source record · open_access_lmu · Other · License: Unknown
Conceptio Open Knowledge Archive — counts are materialised per sync from the index (real full-text coverage, never license entitlement).